Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche Partners With Toyama

July 2, 2007 | A version of this story appeared in Volume 85, Issue 27

Roche and Japan's Toyama Chemical will pursue the development and commercialization of Toyama's new oral rheumatoid arthritis compound T-5224 as well as possible backup drug candidates. Early-stage clinical trials are testing the ability of T-5224 to block a key inflammatory process leading to arthritis symptoms and progressive joint and bone destruction. In exchange for worldwide rights outside Japan, Roche has committed to paying up-front and potential milestone fees that could total $370 million. Beyond retaining product rights in its home country, Toyama will receive royalties on any sales of the drug by Roche.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.